AVRO Stock Price, Avrobio Inc Quote, Chart

Market Summary

USD1.390.00

Delayed

0.00%

AVRO Stock Price

View Fullscreen

AVRO RSI Chart

AVRO Valuation

Market Cap

62.4M

Price/Earnings (Trailing)

2.06

Price/Sales (Trailing)

25.79

Price/Free Cashflow

-1.24

AVRO Price/Sales (Trailing)

AVRO Profitability

Return on Equity

34.11%

Return on Assets

32.82%

Free Cashflow Yield

-80.89%

AVRO Fundamentals

AVRO Revenue

Revenue (TTM)

2.4M

Rev. Growth (Yr)

8.55%

Rev. Growth (Qtr)

-10.22%

AVRO Earnings

Earnings (TTM)

30.3M

Earnings Growth (Yr)

72.72%

Earnings Growth (Qtr)

22.5%

Breaking Down AVRO Revenue

Last 7 days

13.0%

Last 30 days

13.9%

Last 90 days

7.8%

Trailing 12 Months

65.5%

How does AVRO drawdown profile look like?

AVRO Financial Health

Current Ratio

26.17

AVRO Investor Care

Shares Dilution (1Y)

1.79%

Diluted EPS (TTM)

0.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	71.4M	0	36.9M	2.4M
2022	0	0	84.9M	105.9M
2021	21.8M	42.8M	63.8M	0
2020	0	0	0	719.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avrobio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	golipour azadeh	sold (taxes)	-14,698	1.2016	-12,232	chief technology officer
Feb 05, 2024	avruch steven	sold (taxes)	-12,996	1.202	-10,812	chief legal officer
Feb 05, 2024	ridha essra	sold (taxes)	-20,353	1.2006	-16,953	chief medical officer
Feb 05, 2024	ostrowski erik	sold (taxes)	-15,745	1.202	-13,099	interim ceo, president and cfo
Feb 01, 2024	avruch steven	acquired	-	-	32,834	chief legal officer
Feb 01, 2024	ostrowski erik	acquired	-	-	40,084	interim ceo, president and cfo
Feb 01, 2024	ridha essra	acquired	-	-	32,834	chief medical officer
Feb 01, 2024	golipour azadeh	acquired	-	-	37,334	chief technology officer
Jun 12, 2023	golipour azadeh	sold (taxes)	-6,634	1.1903	-5,574	chief technology officer
Jan 24, 2023	mackay geoffrey	acquired	41,859	0.91	45,999	president & ceo

Which funds bought or sold AVRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-17.64	-1,157	3,987	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	11.77	18,728	379,264	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	13,409	13,409	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	new	-	1,091,590	1,091,590	0.11%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-12.62	-74,763	346,179	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	11.42	15,873	342,255	0.01%
May 15, 2024	Royal Bank of Canada	unchanged	-	-1,000	2,000	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-15.17	-141,283	559,411	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-11,268	180,291	-%
May 15, 2024	MORGAN STANLEY	reduced	-74.58	-650,005	204,428	-%

Are Funds Buying or Selling AVRO?

Are funds buying AVRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVRO

No. of Funds

Unveiling Avrobio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	newtyn management, llc	6.1%	2,734,175	SC 13G
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Feb 13, 2024	gmt capital corp	0.0%	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	9.0%	4,001,627	SC 13G/A
Jan 24, 2024	farallon capital partners, l.p.	0.0%	0	SC 13G/A
Jul 24, 2023	bml investment partners, l.p.	8.0%	3,545,396	SC 13G
Jun 06, 2023	tang capital partners lp	6.1%	2,705,000	SC 13G
Feb 17, 2023	farallon capital partners, l.p.	1.3%	563,900	SC 13G
Feb 08, 2023	k2 principal fund, l.p.	0.00%	10	SC 13G/A
Jan 19, 2023	gmt capital corp	2.9%	1,263,483	SC 13G/A

Recent SEC filings of Avrobio Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 15, 2024	3/A	Insider Trading
May 15, 2024	3	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 03, 2024	424B3	Prospectus Filed
May 03, 2024	EFFECT	EFFECT
Apr 29, 2024	S-4/A	Mergers and Acquisition
Apr 15, 2024	S-4/A	Mergers and Acquisition
Apr 04, 2024	425	Prospectus Filed
Mar 26, 2024	S-4/A	Mergers and Acquisition

Peers (Alternatives to Avrobio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Avrobio Inc News

Latest updates

Avrobio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-10.2%	1,146	1,277	1,407	1,056	705	353	2.00	9.00	-	-
Operating Expenses	-17.5%	7,941	9,627	21,091	25,220	25,257	22,985	32,620	31,375	26,884	28,064
S&GA Expenses	-100.0%	-	5,237	6,262	7,887	7,120	7,066	9,577	8,831	8,357	8,477
R&D Expenses	-84.4%	683	4,390	14,829	17,333	18,137	15,919	23,043	22,544	18,527	19,587
Interest Expenses	-	-	-	-	463	423	374	-	-	-	-
Net Income	22.5%	-6,808	-8,785	-21,577	-24,957	-25,034	-22,969	-32,613	-31,387	-26,899	-28,131
Net Income Margin	149.3%	12.52*	5.02*	-0.11*	-1.41*	-1*	-1.29*	-1.87*	-2.88*	-5.55*	-
Free Cashflow	5.8%	-7,569	-8,031	-20,223	-20,292	-23,673	-16,501	-25,091	-21,194	-27,454	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.7%	92.00	101	111	134	83.00	104	129	146	175	204	216	238	246	271	233	256	270	201	217	102	117
Current Assets	-8.4%	92.00	100	109	129	77.00	100	126	142	171	199	212	234	242	267	229	251	265	196	214	98.00	114
Cash Equivalents	-7.0%	91.00	98.00	106	125	72.00	93.00	116	132	162	190	201	226	233	260	220	244	258	188	206	90.00	108
Net PPE	-	-	-	-	2.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	4.00	3.00	4.00	3.00	3.00	3.00
Liabilities	-44.8%	4.00	6.00	8.00	12.00	30.00	29.00	31.00	28.00	32.00	34.00	23.00	17.00	13.00	17.00	25.00	16.00	13.00	15.00	10.00	9.00	11.00
Current Liabilities	-44.8%	4.00	6.00	8.00	12.00	14.00	13.00	16.00	13.00	17.00	19.00	23.00	17.00	13.00	17.00	25.00	15.00	13.00	14.00	10.00	9.00	10.00
Shareholder's Equity	-6.2%	89.00	95.00	103	122	53.00	75.00	98.00	118	143	169	194	221	233	254	208	240	257	186	207	93.00	107
Retained Earnings	-1.4%	-484	-477	-468	-446	-514	-489	-464	-441	-413	-383	-355	-322	-291	-264	-236	-199	-170	-144	-122	-104	-88.84
Additional Paid-In Capital	0.2%	573	572	571	569	567	565	562	560	557	553	549	544	524	519	444	439	427	331	329	198	196
Shares Outstanding	0.5%	45.00	45.00	45.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	37.00	-	-	-	34,838	-	-	-	337	-	-	-	534	-	-	-	289	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.8%	-7,569	-8,031	-20,223	-14,652	-20,284	-23,673	-16,415	-29,106	-28,014	-25,897	-24,824	-19,965	-27,339	-30,488	-24,863	-21,018	-22,434	-18,583	-13,382	-17,965	-17,738
Share Based Compensation	44.6%	878	607	2,220	1,534	2,530	2,255	2,656	3,233	3,378	4,085	5,168	4,691	4,635	4,102	4,805	3,899	2,822	1,885	1,797	1,663	1,455
Cashflow From Investing	-100.0%	-	150	1,198	83,736	-8.00	-	-86.00	-149	-32.00	-850	-267	-1,229	-115	-81.00	-31.00	-488	-577	-766	-78.00	-401	-340
Cashflow From Financing	-49.2%	30.00	59.00	178	-16,321	55.00	59.00	60.00	1.00	142	14,945	22.00	14,605	799	70,705	60.00	8,191	93,663	30.00	129,474	238	252

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVRO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 683	$ 17,333
General and administrative	7,258	7,887
Total operating expenses	7,941	25,220
Loss from operations	(7,941)	(25,220)
Other income:
Interest income, net	1,146	248
Other (expense) income, net	(13)	15
Total other income, net	1,133	263
Net loss and comprehensive loss attributable to common stockholders-basic and diluted	$ (6,808)	$ (24,957)
Net loss per share - basic	$ (0.15)	$ (0.57)
Net loss per share - diluted	$ (0.15)	$ (0.57)
Weighted-average common shares outstanding - basic	44,791	44,037
Weighted-average common shares outstanding - diluted	44,791	44,037

AVRO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 90,481	$ 98,020
Restricted cash	283	283
Prepaid expenses and other current assets	1,074	1,958
Total current assets	91,838	100,261
Operating lease assets	110	432
Restricted cash, net of current portion	400	400
Total assets	92,348	101,093
Current liabilities:
Accounts payable	243	27
Accrued expenses and other current liabilities	3,042	5,449
Operating lease liabilities	224	878
Total current liabilities	3,509	6,354
Total liabilities	3,509	6,354
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 150,000 shares authorized; 44,882 and 44,654 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	572,918	572,010
Accumulated deficit	(484,083)	(477,275)
Total stockholders’ equity	88,839	94,739
Total liabilities and stockholders’ equity	$ 92,348	$ 101,093

About Avrobio Inc

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

WEBSITE	avrobio.com
INDUSTRY	Biotechnology
EMPLOYEES	78

Avrobio Inc Frequently Asked Questions

What is the ticker symbol for Avrobio Inc? What does AVRO stand for in stocks?

AVRO is the stock ticker symbol of Avrobio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avrobio Inc (AVRO)?

As of Fri May 17 2024, market cap of Avrobio Inc is 62.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVRO stock?

You can check AVRO's fair value in chart for subscribers.

What is the fair value of AVRO stock?

You can check AVRO's fair value in chart for subscribers. The fair value of Avrobio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avrobio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avrobio Inc a good stock to buy?

The fair value guage provides a quick view whether AVRO is over valued or under valued. Whether Avrobio Inc is cheap or expensive depends on the assumptions which impact Avrobio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVRO.

What is Avrobio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AVRO's PE ratio (Price to Earnings) is 2.06 and Price to Sales (PS) ratio is 25.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVRO PE ratio will change depending on the future growth rate expectations of investors.